Growth Trends in the Immunotherapy Drugs Industry 2025-2030, by Drug Type, Indication and Region - Revenues to Grow from $268.6 Billion in 2024 to a Projected $577.2 Billion by 2030
21. Januar 2025 04:08 ET
|
Research and Markets
Dublin, Jan. 21, 2025 (GLOBE NEWSWIRE) -- The "Immunotherapy Drugs Market Size, Share & Trends Analysis by Drug Type, Indication, and Region, 2025-2030" report has been added to ...
Alternative Cancer Treatment Research and Forecasts 2024-2032: Market Expands with Growing Demand for Holistic Therapies, Personalized Medicine and Integrative Health Approaches
13. Januar 2025 11:47 ET
|
Research and Markets
Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Alternative Cancer Treatment Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering.The global alternative...
Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025
13. Januar 2025 08:00 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
10. Januar 2025 16:30 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock
10. Januar 2025 08:30 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
10. Januar 2025 08:00 ET
|
Barinthus Biotherapeutics
Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is...
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
10. Januar 2025 07:00 ET
|
Immunocore Holdings plc
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma...
Cancer Immunotherapy Global Market Overview 2023-2030, Competitive Analysis of Amgen, AstraZeneca,Bayer, BMS, Eli Lilly, F. Hoffmann-La Roche, GSK, Immunocore, J&J, Merck, Novartis, Pfizer
10. Januar 2025 04:06 ET
|
Research and Markets
Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.The global market for Cancer Immunotherapy...
Calidi Biotherapeutics Announces Proposed Public Offering
08. Januar 2025 16:01 ET
|
Calidi Biotherapeutics, Inc
SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
Molecular Diagnostics for Cancer Market Report 2025: Cancer Companion Diagnostics is Reshaping the Industry
06. Januar 2025 07:27 ET
|
Research and Markets
Dublin, Jan. 06, 2025 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Cancer: Market Forecasts by Cancer Type, Product and Place with Executive and Consultant Guides" report has been added to ...